The Trump administration on Monday singled out powerful new weight-loss drugs including Wegovy and Zepbound as targets in its ...

Ever since the pharmaceutical company Novo Nordisk realized that GLP-1 drugs were useful for more than diabetes, doctors and ...

While the drugs certainly contribute to weight loss and health gains, they also cause a decline in muscle that some doctors ...

In today’s Health Alert, two popular weight loss drugs went head-to-head in a clinical trial – and one came out on top.

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

Tirzepatide (Zepbound) came out on top against semaglutide (Wegovy) for treating obesity in the head-to-head SURMOUNT-5 trial ...

Fox News senior medical analyst Dr. Marc Siegel weighs in on President Donald Trump's pharmaceutical executive order aiming to cut drug prices for Americans. Feeling snacky? Everyone knows you can ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

If a higher body weight is affecting your ability to get around, or you have joint pain from arthritis, it can impair your ...

A KFF survey from 2024 found people had superior weight loss results on Zepbound compared to Wegovy, ...